Prediction Case File
YouTubeEvaluation Complete

Friends! In this video, I'm going to do a Hims stock analysis

1 extracted signal · 1 resolved · 0 still active

The Patient Investor profile imageThe Patient InvestorIndependent analyst profile
Source published
04 Sept 2025, 20:59 UTC
Recorded by Tahlil Plus
18 May 2026, 20:23 UTC
Video preview for Friends! In this video, I'm going to do a Hims stock analysis
Source overview

AI-generated source summary

The analysis focuses on Hims & Hers Health (HIMS). The stock is currently at $44.46, down approximately 30% over the previous month but up 76% year-to-date. The presenter notes HIMS is trading at roughly three times sales with approximately 54% sales growth and 80% gross margins. A potential lawsuit and related negative media could be ending. The pundit suggests HIMS can obtain a rerating to 6-10 times sales. Expansion into Europe and Canada are also noted. The target price is inferred to be 67.42 with the failure bound set around $40.00. The prediction timeframe is approximately 5 years and the current and predicted trend is that it will become bullish soon.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Evaluation Complete
Signals
1
Extracted from this source
Open
0
Still being tracked
Successful
0
Resolved successfully
Failed
1
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
0%
1 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  3. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

  4. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  5. Market predictions extracted

    1 eligible signal linked to this case.

  6. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

Analyst snapshot

The Patient Investor

Platform-wide history, separate from this source evaluation.

Reliability
47.9
Tracked signals
355
Historical success
34.9%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail